Figure 6
Plans Will Increase Access Barriers Following Approval
of Multiple High-Cost Interferon-Free Regimens1
(Percentage enrollment)
n=41 with 150.5 million total lives
Figure 7
Commercial Health Plans Mandating SP Use for Hepatitis C Products2
(Percentage health plans using external SPs)
n=53, 2010; n=48, 2011; n=52, 2012; n=44, 2013; n=23,
2014
References
1.
2.
3.
36
Health Strategies Group, Managed Care Complete (available as
research subscription service, accessible at www.HealthStrategies.
com), Hepatitis C, October 2013.
Health Strategies Group, Payer Landscape for Specialty
Pharmaceuticals (available as research subscription service,
accessible at www.HealthStrategies.com), Specialty Pharmacy
Management in Commercial Health Plans, February 2014.
Health Strategies Group, Payer Landscape for Specialty
Pharmaceuticals (available as research subscription service,
accessible at www.HealthStrategies.com), Specialty Pharmacy
Management in Managed Medicare and Medicaid, February 2014.